Overview

Study to Evaluate Efficacy, Safety and Tolerability of JNJ-42847922 in Participants With Insomnia Disorder Without Psychiatric Comorbidity

Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to investigate the effect of JNJ-42847922 (change versus placebo) on sleep efficiency (SE) measured by polysomnography (PSG) after single and multiple dose administration to participants with insomnia disorder without psychiatric comorbidity.
Phase:
Phase 2
Details
Lead Sponsor:
Janssen Research & Development, LLC